ALK and non-small cell lung carcinoma: Within the UK, routine epidermal growth factor receptor (EGFR) testing was introduced for patients with stage 3B and 4 NSCLC in 2010, and anaplastic lymphoma kinase (ALK) rearrangement testing became routine in 2012.